The aim of this study was to determine whether the tumor marker EZH2 can be used to evaluate the potential aggressiveness of high-risk localizations of cSCC and to analyze various evaluation methods for its expression. The gene discussed is EZH2; the disease is skin squamous cell carcinoma.